← Back to All US Stocks

Orthofix Medical Inc. (OFIX) Stock Fundamental Analysis & AI Rating 2026

OFIX Nasdaq Surgical & Medical Instruments & Apparatus CIK: 0000884624
Recently Updated • Analysis: Apr 13, 2026 • SEC Data: 2025-12-31
SELL
68% Conf
Pending
Analysis scheduled

📊 OFIX Key Takeaways

Revenue: $822.3M
Net Margin: -11.2%
Free Cash Flow: $-1.3M
Current Ratio: 2.45x
Debt/Equity: 0.35x
EPS: $-2.33
AI Rating: SELL with 68% confidence
Orthofix Medical Inc. (OFIX) receives a SELL rating with 68% confidence from our AI fundamental analysis based on SEC 10-K filings. With revenue of $822.3M, net profit margin of -11.2%, and return on equity (ROE) of -20.5%, Orthofix Medical Inc. demonstrates mixed fundamentals in the Healthcare sector. Below is our complete OFIX stock analysis for 2026.

Is Orthofix Medical Inc. (OFIX) a Good Investment?

Claude

Orthofix is in financial distress following what appears to be a transformative acquisition (4802% revenue growth), but remains unprofitable with -$92.2M net loss and cannot cover interest expenses from operations. While positive operating cash flow and improving loss trends suggest potential recovery, the company faces significant execution risk integrating the acquisition with limited cash cushion ($82M) and breakeven free cash flow.

Why Buy Orthofix Medical Inc. Stock? OFIX Key Strengths

Claude
  • + Strong gross margin of 68.8% indicates pricing power and operational efficiency in core products
  • + Positive operating cash flow of $33.3M despite negative net income suggests underlying business cash generation capability
  • + Improving loss trend with 26.8% YoY net income improvement and 29.4% EPS improvement signals potential operational momentum
  • + Moderate leverage with Debt/Equity of 0.35x and current ratio of 2.45x provide reasonable financial flexibility

OFIX Stock Risks: Orthofix Medical Inc. Investment Risks

Claude
  • ! Company is significantly unprofitable with -$81.4M operating loss and -$92.2M net loss with no clear path to profitability
  • ! Negative interest coverage ratio (-299.4x) means operating income cannot service debt obligations, creating refinancing risk
  • ! Massive 4802% revenue growth almost certainly from acquisition rather than organic growth, indicating integration risk and uncertain value creation
  • ! Free cash flow breakeven (-$1.3M) with capital expenditures nearly equal to operating cash flow leaves minimal margin for error
  • ! Low cash balance of $82M relative to $850.6M asset base and $157.4M long-term debt constrains financial flexibility

Key Metrics to Watch

Claude
  • * Timeline to operating profitability and EBITDA margin expansion
  • * Free cash flow trajectory and sustainability post-acquisition integration
  • * Cash balance preservation and working capital management
  • * Acquisition integration metrics and contribution to consolidated performance
  • * Operating margin improvement rate given existing gross margin strength

Orthofix Medical Inc. (OFIX) Financial Metrics & Key Ratios

Revenue
$822.3M
Net Income
$-92.2M
EPS (Diluted)
$-2.33
Free Cash Flow
$-1.3M
Total Assets
$850.6M
Cash Position
$82.0M

💡 AI Analyst Insight

Strong liquidity with a 2.45x current ratio provides a solid financial cushion.

OFIX Profit Margin, ROE & Profitability Analysis

Gross Margin 68.8%
Operating Margin -9.9%
Net Margin -11.2%
ROE -20.5%
ROA -10.8%
FCF Margin -0.2%

OFIX vs Healthcare Sector: How Orthofix Medical Inc. Compares

How Orthofix Medical Inc. compares to Healthcare sector averages

Net Margin
OFIX -11.2%
vs
Sector Avg 12.0%
OFIX Sector
ROE
OFIX -20.5%
vs
Sector Avg 15.0%
OFIX Sector
Current Ratio
OFIX 2.4x
vs
Sector Avg 2.0x
OFIX Sector
Debt/Equity
OFIX 0.3x
vs
Sector Avg 0.6x
OFIX Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is Orthofix Medical Inc. Stock Overvalued? OFIX Valuation Analysis 2026

Based on fundamental analysis, Orthofix Medical Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.

Return on Equity
-20.5%
Sector avg: 15%
Net Profit Margin
-11.2%
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
0.35x
Sector avg: 0.6x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

Orthofix Medical Inc. Balance Sheet: OFIX Debt, Cash & Liquidity

Current Ratio
2.45x
Quick Ratio
1.43x
Debt/Equity
0.35x
Debt/Assets
47.1%
Interest Coverage
-299.37x
Long-term Debt
$157.4M

OFIX Revenue & Earnings Growth: 5-Year Financial Trend

OFIX 5-year financial data: Year 2021: Revenue $464.5M, Net Income -$28.5M, EPS $-1.51. Year 2022: Revenue $464.5M, Net Income $2.5M, EPS $0.13. Year 2023: Revenue $746.6M, Net Income -$38.4M, EPS $-1.95. Year 2024: Revenue $799.5M, Net Income -$19.7M, EPS $-0.98. Year 2025: Revenue $822.3M, Net Income -$151.4M, EPS $-4.12.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: Orthofix Medical Inc.'s revenue has grown significantly by 77% over the 5-year period, indicating strong business expansion. The most recent EPS of $-4.12 indicates the company is currently unprofitable.

OFIX Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
-0.2%
Free cash flow / Revenue

OFIX Quarterly Earnings & Performance

Quarterly financial performance data for Orthofix Medical Inc. including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q3 2025 $196.6M -$14.1M $-0.57
Q2 2025 $198.6M -$14.1M $-0.36
Q1 2025 $188.6M -$36.0M $-0.95
Q3 2024 $184.0M -$27.4M $-0.71
Q2 2024 $187.0M -$33.4M $-0.88
Q1 2024 $175.2M -$36.0M $-0.95
Q3 2023 $114.0M $2.5M $-0.53
Q2 2023 $118.1M -$2.0M $-0.10

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

Orthofix Medical Inc. Dividends, Buybacks & Capital Allocation

Operating Cash Flow
$33.3M
Cash generated from operations
Stock Buybacks
$63.4M
Shares repurchased (TTM)
Capital Expenditures
$34.6M
Investment in assets
Dividends
None
No dividend program

OFIX SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for Orthofix Medical Inc. (CIK: 0000884624)

📋 Recent SEC Filings

Date Form Document Action
Apr 9, 2026 8-K ofix-20260409.htm View →
Mar 19, 2026 4 xslF345X06/ownership.xml View →
Mar 10, 2026 4 xslF345X05/ownership.xml View →
Mar 6, 2026 4 xslF345X05/ownership.xml View →
Mar 6, 2026 4 xslF345X05/ownership.xml View →

Frequently Asked Questions about OFIX

What is the AI rating for OFIX?

Orthofix Medical Inc. (OFIX) has an AI rating of SELL with 68% confidence, based on fundamental analysis of SEC EDGAR filings.

What are OFIX's key strengths?

Claude: Strong gross margin of 68.8% indicates pricing power and operational efficiency in core products. Positive operating cash flow of $33.3M despite negative net income suggests underlying business cash generation capability.

What are the risks of investing in OFIX?

Claude: Company is significantly unprofitable with -$81.4M operating loss and -$92.2M net loss with no clear path to profitability. Negative interest coverage ratio (-299.4x) means operating income cannot service debt obligations, creating refinancing risk.

What is OFIX's revenue and growth?

Orthofix Medical Inc. reported revenue of $822.3M.

Does OFIX pay dividends?

Orthofix Medical Inc. does not currently pay dividends.

Where can I find OFIX SEC filings?

Official SEC filings for Orthofix Medical Inc. (CIK: 0000884624) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is OFIX's EPS?

Orthofix Medical Inc. has a diluted EPS of $-2.33.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.

Is OFIX a good stock to buy right now?

Based on our AI fundamental analysis in April 2026, Orthofix Medical Inc. has a SELL rating with 68% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.

Is OFIX stock overvalued or undervalued?

Valuation metrics for OFIX: ROE of -20.5% (sector avg: 15%), net margin of -11.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

Should I buy OFIX stock in 2026?

Our dual AI analysis gives Orthofix Medical Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is OFIX's free cash flow?

Orthofix Medical Inc.'s operating cash flow is $33.3M, with capital expenditures of $34.6M. FCF margin is -0.2%.

How does OFIX compare to other Healthcare stocks?

Vs Healthcare sector averages: Net margin -11.2% (avg: 12%), ROE -20.5% (avg: 15%), current ratio 2.45 (avg: 2).

Top Rated Stocks
NSSC 92% MLI 92% MELI 92% MDXG 92% MANH 92% INVA 92% GGG 92% GCT 92% FTNT 92% FSLR 92%
Sector: All Healthcare Stocks →
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Apr 13, 2026 | Data as of: 2025-12-31 | Powered by Claude AI